argenx (ARGX) traded higher as investors repositioned ahead of a key near-term catalyst: new VYVGART (efgartigimod) data scheduled for the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago on April 18–22, 2026. In a March 6, 2026 update, the company outlined that its AAN program will include Phase 3 ADAPT OCULUS results in ocular myasthenia gravis, additional Phase 3 ADAPT SERON data in generalized myasthenia gravis patients without detectable AChR antibodies, and expanded CIDP analyses (including biomarker and real-world evidence work). (argenx.com)

The AAN lineup puts emphasis on potential label expansion and deeper evidence in myasthenia gravis subtypes, as well as reinforcing the commercial durability of VYVGART in CIDP. Markets tend to re-rate late-stage immunology leaders into major medical-meeting readouts when investors believe the dataset can expand addressable patients, support physician confidence, or provide cleaner segmentation for payers and prescribers.

Beyond the medical-meeting setup, ARGX has had a supportive analyst-tone backdrop in recent weeks. A notable example is a March 2026 reiteration of an Outperform rating with a $1,000 price target, which has helped keep the narrative anchored on upside tied to VYVGART’s expansion opportunities and pipeline optionality. (benzinga.com)

Near-term attention is likely to remain on specifics of the AAN presentations—especially how robust and clinically meaningful the ocular MG ADAPT OCULUS dataset looks, and whether CIDP analyses suggest broader or earlier use dynamics. Investors will also watch for any incremental regulatory or commercialization commentary that could emerge as the meeting approaches (April 18–22, 2026). (argenx.com)